Novo Nordisk (NVO) Q1 2025 profits

Novo Nordsk On Wednesday, I reported a better rise than expected in the net profit, but it reduced sales growth expectations throughout the full year amid weaker sales of weight loss medications in Wegovy.

The net profit of the Danish Pharmaceutical Giant, 29.03 billion Danish Crohn (4.4 billion dollars) for a period of three months until the end of March, before the 27.8 billion Danish Croner.

The famous Wegovy Pongisity sales reached 17.36 billion kroner over the course of this period, just less than 18.51 billion Kroner Crohner, which analysts expected in the FactSet survey on Tuesday.

The total revenue in Novo Nordisk – which also produces diabetes and rare disease treatments – was 78.09 billion Danish Kroner against a Danish Kroner 78.18 million.

Over the course of 2025, the company now sees sales growth by 13 % to 21 % in fixed exchange rates, less than 16 % to 24 % of expectations in February.

The CEO of Novo Nordisk Lars Fruergaard jditionsan attributed the low prediction to the high competition of complex weight loss medications in the United States

“In the first quarter of 2025, we have achieved 18 % growth in sales and we continued to expand the scope of innovative GLP-1 treatments,” Yorgensen said in a statement.

“However, we have reduced our perception of the entire year due to the planned GLP-1 penetration in Lowerthan, which is affected by the rapid expansion of the double in the United States.”

The combat of American pharmacies has been allowed to create legal copies of Wegovy and Diabros in Novo under drug shortage by the Food and Drug Administration (FDA).

The Food and Drug Administration (FDA) announced in February that the shortage has ended, which gave compound pharmacies until May 22 to stop selling copies of the drug. However, Jentsensen repeated on Wednesday that the company You will continue companies It continues to distribute these imitated imitated medications.

However, the company struggled to get rid of negative feelings after a series of Disappointed experimental results For obesity drug candidate from the next generation.

Competition competing in the weight loss drug market, with pharmaceutical companies including Rushand Astrazeneca and Exhausted All growth currently Possible new candidates.

The main United States competitor in Novo Eli Lily On Thursday I reported expectations 45 % in sales in the first quarterAlthough its famous weight loss revenues were slightly lower than expected to drop the prices of drugs. The USA drug maker also reduced the entire year profit instructions due to the fees related to the modern cancer treatment deal, which led to a decrease in shares.